MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/art.41456

Медицинская библиотека · Arthritis & rheumatology (Hoboken, N.J.) · 2020

COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes.

Haberman Rebecca H, Castillo Rochelle, Chen Alan, Yan Di, Ramirez Deborah, Sekar Vaish, Lesser Robert, Solomon Gary, Neimann Andrea L, Blank Rebecca B, Izmirly Peter, Webster Dan E, Ogdie Alexis, Troxel Andrea B, Adhikari Samrachana, Scher Jose U, NYU WARCOV Investigators

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To characterize the hospitalization and death rates among patients with inflammatory arthritis (IA) affected by coronavirus disease 2019 (COVID-19) and to analyze the associations of comorbidities and immunomodulatory medications with infection outcomes.

METHODS

Data on clinical and demographic features, maintenance treatment, disease course, and outcomes in individuals with IA (rheumatoid arthritis and spondyloarthritis) with symptomatic COVID-19 infection were prospectively assessed via web-based questionnaire followed by individual phone calls and electronic medical record review. Baseline characteristics and medication use were summarized for hospitalized and ambulatory patients, and outcomes with the different medication classes were compared using multivariable logistic regression.

RESULTS

A total of 103 patients with IA were included in the study (80 with confirmed COVID-19 and 23 with high suspicion of COVID-19). Hospitalization was required in 26% of the participants, and 4% died. Patients who were hospitalized were significantly more likely to be older (P < 0.001) and have comorbid hypertension (P = 0.001) and chronic obstructive pulmonary disease (P = 0.02). IA patients taking oral glucocorticoids had an increased likelihood of being admitted for COVID-19 (P < 0.001), while those receiving maintenance anticytokine biologic therapies did not.

CONCLUSION

Among patients with underlying IA, COVID-19 outcomes were worse in those receiving glucocorticoids but not in patients receiving maintenance anticytokine therapy. Further work is needed to understand whether immunomodulatory therapies affect COVID-19 incidence.

Для цитирования: Haberman Rebecca H, Castillo Rochelle, Chen Alan, Yan Di, Ramirez Deborah, Sekar Vaish, Lesser Robert, Solomon Gary, Neimann Andrea L, Blank Rebecca B, Izmirly Peter, Webster Dan E, Ogdie Alexis, Troxel Andrea B, Adhikari Samrachana, Scher Jose U, NYU WARCOV Investigators. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes.. Arthritis & rheumatology (Hoboken, N.J.). 2020. DOI: 10.1002/art.41456.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.